Antidepressants

by Feighner, J. P.; Stanga, Christina Y.; Preskorn, Sheldon H., M.D.; Ross, Ruth

• ISBN13: 9783540430544
• ISBN10: 3540430547
• Format: Hardcover
• Copyright: 2004-04-01
• Publisher: Springer Verlag

Summary

This book is being published as we mark the end of the first 50 years of the modern antidepressant era. This era began with the chance discovery that tricyclic antidepressants and monoamine oxidase inhibitors had antidepressant properties. That discovery had three consequences. First, it brought simple and effective treatment to patients suffering from major depressive illnesses. Second, these discoveries, together with the discovery of lithium and chlorpromazine, began the remedicalization of psychiatry by making it clear that the treatment of many of the major psychiatric illnesses can be approached in the same way as other medical conditions. The goal of this book is to provide a thorough review of the current status of antidepressants - how we arrived at this point in their evolution and where we are going in both the near and the long term. It employs both a scientific and historical approach to accomplish these goals. This volume is intended for practitioners who use antidepressants on a daily basis in their practice as well as for the student and researcher. Each will find that it provides a comprehensive and logical approach to this important group of medications.

Table of Contents

Part 1. Basic Principles: Pharmacologic Science
Biochemical and Physiological Processes in Brain Function and Drug Actions	3	(32)
W.D. Horst
General Principles of Pharmacokinetics	35	(52)
S.H. Preskorn, M.L. Catterson
Therapeutic Drug Monitoring of Antidepressants	87	(30)
M.J. Burke, S.H. Preskorn
Part 2. Basic Principles: Clinical Science
Biological Markers of Depression	117	(32)
T.J. Connor, B.E. Leonard
Quality of Life and Rating Scales of Depression	149	(22)
P. Bech
Part 3. Current Pharmacotherapy of Major Depressive Disorder
Overview of Currently Available Antidepressants	171	(14)
S.H. Preskorn, R. Ross
Tricyclic Antidepressants	185	(24)
M. Lader
Monoamine Oxidase Inhibitors	209	(32)
S.H. Kennedy, A. Holt, G.B. Baker
Selective Serotonin Reuptake Inhibitors	241	(22)
S.H. Preskorn, R. Ross, C.Y. Stanga
Other Antidepressants	263	(62)
S.H. Preskorn, R. Ross
Current Role of Herbal Preparations	325	(30)
D. Wheatley
Part 4. Use of Antidepressants in Special Populations
Children and Adolescents	355	(24)
J. F. Bober, S.H. Preskorn
Women	379	(14)
K.A. Yonkers, O. Brawman-Mintzer
Older Adults	393	(28)
S. Glover, W.F. Boyer
Bipolar Mood Disorders	421	(26)
R.D. Alarcon
Treatment-Refractory Depression	447	(42)
M. Trivedi, T. Bettinger, B. Kleiber
Personality Disorders	489	(30)
M.L. Wainberg, A.J. Kolodny, L.J. Siever
Part 5. Future Directions in the Treatment of Major Depressive Disorder
New Hypotheses to Guide Future Antidepressant Drug Development	519	(46)
I. Nalepa, F. Sulser
Promising New Directions in Antidepressant Development	565	(18)
V. Garlapati, W.F. Boyer, J.P. Feighner
Role of Pharmacogenetics/Pharmacogenomics in the Development of New Antidepressants	583	(14)
S.H. Preskorn
Appendix	597	(12)
Subject Index	609